You are viewing: North America AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The North America AI in Life Science Market was valued at $5696.5 Million in 2026 and projected to reach to $17877.5 Million by 2031, representing a compound annual growth rate of 25.7%. North America's AI in Life Science market is poised for sustained expansion through 2031, driven by increasing adoption of machine learning in drug discovery, clinical trial optimization, and personalized medicine initiatives.

North America AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

North America AI in Life Science Market Trends and Insights

  • North America leads global adoption of AI technologies in life sciences, driven by advanced healthcare infrastructure, significant R&D investments, and a concentration of biotechnology and pharmaceutical companies.
  • The region's strong regulatory framework and digital health ecosystem position North America as a critical hub for AI-enabled drug discovery, clinical diagnostics, and personalized medicine solutions. During the 2026–2031 forecast period, North America will witness accelerated integration of machine learning and AI across genomics, precision medicine, and clinical trial optimization.
  • North America's competitive advantage stems from its established venture capital landscape, academic research institutions, and early adoption of emerging technologies.
  • The region's healthcare providers and life science organizations are increasingly leveraging AI to enhance operational efficiency, reduce time-to-market for therapeutics, and improve patient outcomes, solidifying North America's dominance in the global AI life science sector..

Key Market Statistics

  • CAGR (2026-2031) 25.7% CAGR
  • Market Size, 2026 ~USD 5696.5 Million
  • Forecast, 2031 ~USD 17877.5 Million
  • Geography North America

North America AI in Life Science Market Overview

Market Leadership Position :

North America commands the largest share of the global AI in Life Science market, with the US alone valued at $29,746.2 million in 2026, representing over 80% of the regional market and driving innovation across the sector.

Accelerated Growth Trajectory :

The North American market is projected to grow from $5,696.5 million in 2026 to $17,877.5 million by 2031, representing a 25.7% CAGR, outpacing many global regions and reflecting strong institutional adoption of AI technologies.

Robust R&D Infrastructure :

North America benefits from world-class research institutions, substantial venture capital funding, and a concentration of Fortune 500 pharmaceutical and biotechnology companies actively investing in AI-driven drug discovery and development solutions.

Regulatory Advancement :

The region's mature regulatory framework, including FDA guidance on AI/ML in medical devices and drug development, provides clarity for market participants and accelerates the commercialization of AI-enabled life science solutions.

North America AI in Life Science Market Dynamics

  • The region's competitive advantage stems from its advanced healthcare infrastructure, significant capital availability, and collaborative ecosystem between academia, industry, and government agencies.
  • Major pharmaceutical and biotech firms are rapidly integrating AI capabilities into their R&D pipelines, while emerging startups continue to innovate in specialized applications. The forecast period will witness accelerated digital transformation across North American life sciences, with AI applications expanding into genomics, protein folding, and real-world evidence analysis.
  • Regulatory clarity from the FDA and Health Canada will further facilitate market growth, while strategic partnerships between technology companies and life science organizations will unlock new value creation opportunities.
  • Investment in AI talent and infrastructure will remain critical to maintaining North America's global leadership position in this high-growth sector..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • North America's AI in Life Science Market will grow from $5,696.5M (2026) to $17,877.5M (2031) at a 25.7% CAGR.
    • North America leads global AI adoption in life sciences due to advanced infrastructure, robust R&D funding, and regulatory support.
    • North America's pharmaceutical and biotech sectors are accelerating AI integration for drug discovery, clinical trials, and precision medicine.
    • North America's venture capital ecosystem and academic institutions drive innovation and competitive advantage in AI life science applications.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    North America AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    Target Audience

    • Pharmaceutical & Biotech Executives : C-suite leaders and R&D directors require North America-specific market intelligence to guide AI investment decisions, competitive positioning, and strategic partnerships within the region's dominant life science ecosystem.
    • AI & Software Vendors : Technology companies targeting the North American life science market need detailed regional insights on customer segments, adoption barriers, regulatory requirements, and competitive dynamics to optimize go-to-market strategies.
    • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in North American AI life science companies require market sizing, growth forecasts, and competitive analysis to support due diligence and portfolio management decisions.
    • Contract Research Organizations (CROs) : CRO leaders need North America market data to understand AI adoption trends among pharmaceutical clients, identify service expansion opportunities, and benchmark their AI capabilities against regional competitors.
    • Healthcare Policy & Regulatory Bodies : Government agencies and regulatory organizations use market research to inform policy development, understand industry trends, and ensure appropriate oversight of AI applications in drug development and clinical practice.

    Key Companies in the North America AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    North America vs. other regions

    HowNorth America compares to the other 3 regional blocs covered in this market.

    Europe
    ~USD 8828.7 Million · 26.4% wtd CAGR ·
    Asia Pacific
    ~USD 8208.2 Million · 26.7% wtd CAGR ·
    Latin America
    ~USD 1294.1 Million · 24.9% wtd CAGR ·
    Middle East & Africa
    ~USD 1074 Million · 25.5% wtd CAGR ·

    Countries within North America - compare and drill down

    Country2025 size (native)
    USUSD 29746.2 Million
    CanadaUSD 3136.5 Million

    Country market size visualization

    US
    USD 29746.2 Million
    Canada
    USD 3136.5 Million

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuations for North America ($5.7B in 2026, $17.9B in 2031) with country-level breakdowns for the US and Canada, enabling accurate budget allocation and revenue projections for regional expansion strategies.
    • Competitive Landscape Intelligence : Understand the competitive positioning of North American AI vendors, pharmaceutical leaders, and biotech innovators, identifying key players driving market consolidation and partnership opportunities in the region.
    • Regulatory & Compliance Insights : Access detailed analysis of FDA guidance, Health Canada regulations, and emerging compliance frameworks specific to AI/ML in life sciences, reducing market entry risks and accelerating product commercialization timelines.
    • Investment & Growth Opportunities : Identify high-potential segments within North America's AI life science ecosystem, including drug discovery, clinical trials, genomics, and personalized medicine, with clear growth drivers and market gaps for strategic investment.
    • Technology Adoption Trends : Gain insights into North American adoption rates of AI technologies across pharmaceutical, biotech, and CRO sectors, including barriers to adoption, implementation best practices, and ROI benchmarks for informed decision-making.

    Frequently asked questions

    What is the projected market size of AI in Life Science in North America by 2031?

    North America's AI in Life Science Market is projected to reach $17,877.5 million by 2031, up from $5,696.5 million in 2026.

    What is the CAGR for AI in Life Science in North America?

    North America's AI in Life Science Market is expected to grow at a compound annual growth rate (CAGR) of 25.7% from 2026 to 2031.

    What are the primary drivers of AI adoption in North America's life science sector?

    North America's AI adoption is driven by advanced healthcare infrastructure, substantial R&D investments, regulatory support, a strong venture capital ecosystem, and the concentration of leading pharmaceutical and biotechnology companies.

    How is North America leveraging AI in drug discovery and clinical trials?

    North America's life science organizations are using AI for accelerated drug discovery, optimizing clinical trial design and patient recruitment, improving diagnostic accuracy, and enabling precision medicine approaches.

    What competitive advantages does North America hold in the AI life science market?

    North America benefits from established academic research institutions, robust venture capital funding, early technology adoption, regulatory clarity, and a concentration of skilled AI and life science talent.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status